Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HSP-638 by Zhejiang Boyiao Biopharmaceutical for Graves' Ophthalmopathy: Likelihood of Approval
HSP-638 is under clinical development by Zhejiang Boyiao Biopharmaceutical and currently in Phase I for Graves' Ophthalmopathy. According to GlobalData,...